Ctt Pharmaceutical Holdings, Inc. · OTC:CTTH
Ctt Pharmaceutical — Investor Presentation (August 2020)
22 slides from Ctt Pharmaceutical's investor presentation, August 2020
Slide 1: Novel Drug Delivery Technologies
Novel Drug Delivery Technologies CORPORATE PRESENTATION AUGUST 2020
Slide 2: Forward Looking Statements
Forward Looking Statements Except for the historical information contained herein, the matters discussed in this PPT release are forward looking statements within the meaning of the federal securities laws. Important factors could cause our actual results to differ materially from those contained in
Slide 3: Novel Drug Delivery Technologies Set for International Expansion
Novel Drug Delivery Technologies Meeting underserved needs in large target markets Successfully commercialized first Strong IP portfolio Developing new product lines product Multiple patents Multiple active ingredients Clinically proven Applied in over 50 countries Targeting pharmaceutical, High bio
Slide 4: The Product – CTT’s Sublingual Dissolvable Wafer
The Product – CTT’s Sublingual Dissolvable Wafer CTT has developed a patented oral fast- • CTT uses a novel form of encapsulation of the active dissolving drug delivery system, a thin film, ingredient, comparable to a soap bubble. dissolvable wafer, suitable for the administration of a wide variety
Slide 5: Our Wafer Meets Major Market Needs
Our Wafer Meets Major Market Needs • Accurate and consistent dosing precisely determined and consistent potency of the active ingredient, a critical advantage over most other form factors • Rapid onset CTT’s strips dissolve quickly in the oral cavity (5-15 seconds), with the active ingredient rapidl
Slide 6: Clinically Proven
Clinically Proven Human Trials on Pain Relief Study Outcomes Objectives High bioavailability • Determine the efficacy (effect, or bio- • The dose ranging studies indicated that availability) of wafers containing bioavailability is comparable to intravenous THC/CBD as the active, pain relieving injec
Slide 7: Commercially Proven Cannabis Infused Product
Commercially Proven Cannabis Infused Product FIRST RUN SOLD OUT1 1 Introduced under Aurora DissolveTM brand, marketed to Aurora registered medical patients only, reflecting a penetration rate of approximately 4% in less than 60 days
Slide 8: Sublinguals Command Price Premium
Sublinguals Command Price Premium “Users of tinctures, sublinguals, capsules and topicals are often categorized as health and wellness consumers, and, in general, they’re willing to pay a higher price for those products because they’re marketed with having specific effects – pain relief, sleep or re
Slide 9: Market Dynamics Require Innovation
Market Dynamics Require Innovation Increasing recognition of health benefits is driving demand for new medical and wellness products • Growing body of science-based evidence supports medical efficacy of products such as cannabinoids, psychedelics and natural health products, resulting in strong mark
Slide 10: Medical Applications
Medical Applications A growing body of anecdotal and Potential medical active scientific evidence supports the efficacy of certain natural ingredients for strip delivery Accurate (micro) dosing ingredients in the successful treatment of symptoms related • Pharmaceuticals Rapid onset of action to maj
Slide 11: Clinical Trial Data
Clinical Trial Data Comperison Oral THC and CBD Wafers with THC Cookie Blood Levels Comparison vm Vaporizer, Wafer and Gum Decrease in Pain Score (THC:CBD 1:1) 3 times Daily » 200 00 ~ = al #00 a+ Pain Score 200 af 2” : 2+ oo a4 v rr en 0 $10 1S 30 45 oO 120 160 240 350 4H 720 Tein) ot Time fie) Tim
Slide 12: Patent Protected Process & Products
Patent Protected Process & Products Patent Series #1 - Opioids Patents: • US 8623401 ISSUED • Canadian 2624110 ISSUED • The patent covers orally administrable wafers comprising a film forming agent that forms a gel, and also the process of making the wafers by exposing the gel to heating and cooling
Slide 13: The Opportunity - Cannabinoids
The Opportunity - Cannabinoids The Trend: cannabis incidence in the U.S. increased to 15.8% in 2018, up from 11.6% in 2012 (Cowen) • THC • TO BE COMPLETED
Slide 14: The Cannabinoid Opportunity - CBD
The Cannabinoid Opportunity - CBD $20 billion 10% of U.S. population 2024 U.S. CBD market size projected to consume CBD by 2024 49% CAGR 53% of CBD in the U.S. is consumed as 50% of consumers site convenience as their ingestibles number-one reason for choosing ingestibles 33% of people state manufac
Slide 15: The Cannabinoid Opportunity – Form Factors
The Cannabinoid Opportunity – Form Factors • While dried flower remains the dominant form factor, other delivery mechanisms are gaining ground • Especially in the world’s largest legal cannabis market - California – non-combustible form factors are gaining ground on flower • The vape contamination s
Slide 16: The Opportunity - NHPs
The Opportunity - NHPs • A greater focus on preventation, fed by rising health concerns, is resulting in changing lifestyles and dietary habits, driving demand for dietary supplements and other wellbeing products. • “The global dietary supplements market size was estimated at $123.28 billion in 2019
Slide 17: NHP Applications
NHP Applications The ease of use, rapid onset of action, high bioavailability of the active ingredient, zero calorific content, small size and discrete administration provide key advantages in the following NHP and related applications • Melatonin CTT’s strips offer • Vitamin supplements • Omega 3 a
Slide 18: The Opportunity - Pharmaceuticals
The Opportunity - Pharmaceuticals • Medical experts are embracing lower A recent research study by Transparency dosages with quicker absorption producing Market Research found that the global more effective and safer results. This market for thin film drug manufacturing will reduces stress on the li
Slide 19: Products
Products CannaWafe – delivery of cannabinoids for medical purposes. The CannaWafe was successfully introduced onto the market with Aurora Cannabis under the trademark Aurora Dissolve StripsTM Other products under consideration MedWafe - this wafer can delivery a variety of pharmaceutical ingredients
Slide 20: Growth Strategy
Growth Strategy PRODUCT DEVELOPMENT DISTRIBUTION Leveraging IP to develop new SKUs, Expanded business development including CBD, vitamin, melatonin, capabilities with three new nicotine and pharmaceutical appointments to pursue infused strips partnership strategy and drive growth and expansion into
Slide 21: Ease of Retooling Fuels Product Diversification
Ease of Retooling Fuels Product Diversification • The production of CTT’s strips can be done through a manually or automatically controlled process. • Capacity of the automated process is approximately 10 times that of the Limited retooling required in manual set up, with operating costs switching b
Slide 22: Thank You
Thank You
CTT Pharmaceutical Holdings — Investor Presentation (August 2020) on 6ix